Hertz Global Holdings, Inc (NASDAQ:HRZ) navigates challenges with a 1.6% sales growth in Q1 FY24 to $2.08 billion. Despite a $(1.28) adjusted EPS missing estimates, analysts remain cautious. Goldman Sachs reaffirms a Sell rating, cutting the price target to $4 from $7. Concerns linger over HTZ's liquidity and fleet management, with ongoing scrutiny on First Lien Covenant compliance, especially amid a $400 million free cash flow burn projected for FY24.

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent infringement in mRNA technology.

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly.

Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers.